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Despite the important role of fluoroquinolones and the predominant use of ofloxacin for treating multidrug-resistant tuberculo-
sis in South Africa, there are limited data on ofloxacin pharmacokinetics in patients with multidrug-resistant tuberculosis, no
ofloxacin pharmacokinetic data from South African patients, and no direct assessment of the relationship between ofloxacin
pharmacokinetics and the MIC of ofloxacin of patient isolates. Our objectives are to describe ofloxacin pharmacokinetics in
South African patients being treated for multidrug-resistant tuberculosis and assess the adequacy of ofloxacin drug exposure
with respect to the probability of pharmacodynamic target attainment (area under the time curve/MIC ratio of at least 100). Sixty-
five patients with multidrug-resistant tuberculosis were recruited from 2 hospitals in South Africa. We determined the ofloxacin
MICs for the Mycobacterium tuberculosis isolates from baseline sputum specimens. Patients received daily doses of 800 mg
ofloxacin, in addition to other antitubercular drugs. Patients underwent pharmacokinetic sampling at steady state. NONMEM
was used for data analysis. The population pharmacokinetics of ofloxacin in this study has been adequately described. The prob-
ability of target attainment expectation in the study population was 0.45. Doubling the dose to 1,600 mg could increase this to
only 0.77. The currently recommended ofloxacin dose appeared inadequate for the majority of this study population. Studies to
assess the tolerability of higher doses are warranted. Alternatively, ofloxacin should be replaced with more potent
fluoroquinolones.
Multidrug-resistant tuberculosis (MDR-TB), defined as tu-berculosis resistant to rifampin and isoniazid (34), is of in-
creasing concern. Globally, among previously treated TB patients,
18.5% have MDR-TB (37), and 3.2% of all new TB cases are
MDR-TB (7). Fluoroquinolones have improved MDR-TB cure
rates, although development of resistance to quinolones is a con-
cern (10, 11, 22). Ofloxacin is a fluoroquinolone that is routinely
administered to patients with MDR-TB in South Africa in accor-
dance with national guidelines (26). However, ofloxacin has been
found to be less effective than other fluoroquinolones, such as
moxifloxacin and gatifloxacin, in clinical studies (27) and in in
vitro studies (13). Ofloxacin, however, continues to be used for
treatment of tuberculosis, perhaps because it is less expensive. The
levorotatory isomer of ofloxacin, levofloxacin, has been found to
have half the MIC of ofloxacin against Mycobacterium tuberculosis
(13); therefore, it may be expected to be more potent than ofloxa-
cin. Indeed, in mice it has been shown that double the ofloxacin
dose is equivalent in antitubercular activity to the corresponding
levofloxacin dose (18). However, the higher cost of levofloxacin
remains a problem.
Ofloxacin is primarily renally eliminated with a combination
of glomerular filtration and active secretion (19); the respective
proportions of the drug eliminated through glomerular filtration
and extraglomerular means are currently unknown. As expected,
renal function influences ofloxacin elimination (33), that is, clear-
ance decreases with decreasing renal function. Plasma protein
binding is reported to be independent of the ofloxacin concentra-
tion; it was reported to be 25% in healthy volunteers (19) and was
estimated as 32% from in vitro data (16).
The World Health Organization (WHO) suggests a drug sus-
ceptibility testing critical concentration for ofloxacin of 2.0 mg/
liter for both solid and liquid media (35). Patients with MDR-TB
strains with an ofloxacin MIC greater than 2.0 mg/liter should not
receive ofloxacin as part of their treatment but should receive an
alternative drug. The MIC of ofloxacin for clinical Mycobacterium
tuberculosis isolates has been reported to be normally distributed,
ranging between 0.25 and 1 mg/liter (2). However, these data were
from a Swedish hospital, and South African MIC distributions
may differ. Interestingly, susceptibility to ofloxacin has been
shown to be reduced in the presence of rifampin resistance (20).
The pharmacokinetic-pharmacodynamic marker that best
predicts the efficacy of fluoroquinolones, including ofloxacin, is
the ratio of the free fraction of area under the time curve to the
MIC (fAUC/MIC) (31). In vitro murine (29) and clinical studies
have shown that fluoroquinolones have the greatest bacteri-
cidal activity against Mycobacterium tuberculosis and decreased
probability of resistance when the fAUC/MIC ratio is 100 (9,
12, 29–31).
The pharmacokinetics and pharmacodynamics of ofloxacin in
patients with MDR-TB in a routine clinical setting have been stud-
ied to a very limited extent (33) and have not been studied in
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South Africans. This study characterizes ofloxacin pharmacoki-
netics and pharmacodynamics in patients with MDR-TB in the
high-burden South African setting.
MATERIALS AND METHODS
Ethical approval was obtained from the University of Cape Town, the
University of KwaZulu-Natal, the South African Department of Health,
and the U.S. Centers for Disease Control and Prevention.
Clinical procedures. The study was conducted at two MDR-TB refer-
ral hospitals, one in Cape Town and the other in Durban. Patients were
diagnosed with MDR-TB based on results of drug susceptibility tests and
referred to the hospitals as part of routine clinical practice. Sixty-five adult
patients with MDR-TB were recruited into the study before commencing
treatment. Patients received daily weight-based doses of kanamycin (or
amikacin), pyrazinamide, terizidone, and ethionamide, in addition to 800
mg of ofloxacin. All the subjects were inpatients, and drug intake was
directly observed by hospital staff. A baseline sputum sample was ob-
tained from each patient before commencing treatment to determine the
ofloxacin MIC of Mycobacterium tuberculosis. In addition to standard
therapy for MDR-TB, 12 of the 27 patients from Durban received a
600-mg daily dose of linezolid as part of a clinical trial (TBTC Study 30) in
which they were coenrolled. In the TBTC Study 30, the 27 patients from
Durban were randomized to receive 600 mg of linezolid or a placebo daily.
Twelve of these patients actually received linezolid, while the remainder
received the placebo.
Participants underwent pharmacokinetic sampling on one occasion at
least 1 week after commencing treatment to ensure that steady-state phar-
macokinetics had been attained. Patients in Cape Town received the
ofloxacin dose after breakfast (oatmeal porridge, bread, and a cup of tea)
as part of the standard hospital procedure. Patients in Durban received the
ofloxacin dose on an empty stomach. The Cape Town pharmacokinetic
sampling schedule was 0.5, 3.5, 5.5, 7.5, and 12 h after dose administra-
tion, while the Durban sampling schedule was 0, 1, 2, 4, 8, 11, and 24 h
after dose administration. For Durban patients, blood samples were im-
mediately placed on ice after collection and centrifuged and sera were
separated and aliquoted within 30 min. Sera were placed on ice, trans-
ported, and stored at 70°C within 4 h of collection. For Cape Town
patients, blood samples were immediately placed on ice after collection.
Within 10 min thereafter, the samples were centrifuged and the sera were
placed on dry ice before being transferred all at once to a 80°C freezer at
the end of the day. Lithium heparin tubes were used for blood sampling
for both study sites.
Laboratory procedures. The MIC was determined by the agar dilu-
tion method using 2-fold dilutions from an initial concentration of 8.0
mg/liter down to 0.03 mg/liter. Serial ofloxacin concentrations and a
drug-free control were incorporated into Middlebrook 7H10 agar. A 1.0
McFarland standard of each Mycobacterium tuberculosis isolate from the
patients was diluted to 104 before inoculation onto the drug-free control
and drug-containing quadrants. A sensitive M. tuberculosis H37Rv con-
trol and a resistant M. tuberculosis A169 control were set up with each
batch of MIC assays. The inoculated agar plates were allowed to air dry in
a biosafety cabinet and then packed into CO2-permeable plastic bags. The
bags were sealed and incubated at 37°C, and the plates were read after 21
days. The lowest concentration on the agar plate that did not have growth
was recorded as the MIC. The plates were done in triplicate to ensure
reproducibility of the results. Drug plasma concentrations were deter-
mined using a validated high-performance liquid chromatography assay
with tandem mass spectroscopy detection method (21). The assay was
validated over the concentration range of 0.078 mg/liter to 20 mg/liter.
The percent recovery for ofloxacin was greater than 70% and reproducible
at low, medium, and high concentrations (21). The coefficient of variation
during analysis of the study samples ranged from 4.4% to 6.0% and the
accuracy from 94.0% to 102.9% for high, medium and low quality con-
trols, showing that the method had good reproducibility.
Pharmacokinetic analysis. Concentration-time data from the two
study sites were pooled for pharmacokinetic analysis using a nonlinear
mixed effects modeling approach implemented in NONMEM version
7.1.2 (Icon, Inc., Verona, PA). An Intel Fortran compiler was used, and
the runs were executed using Perl-speaks-NONMEM (http://psn
.sourceforge.net/). Population pharmacokinetic parameter estimates and
their variability were obtained using the first-order conditional estimation
method with ε- interaction (FOCE-I). The objective function value (OFV)
and visual predictive checks were used for model building and evaluation. A
decrease in the OFV of at least 3.84 points after the inclusion of one model
parameter was regarded as statistically significant. Various structural models
were evaluated, including a one- and two-compartment model with first-
order elimination and mixed-order elimination. Absorption models that
were evaluated include first-order absorption, zero-order absorption, se-
quential zero-order and first-order absorption, and a transit compartment
(28) absorption model. The effects of covariates on several model parameters
were investigated one at a time in a stepwise manner, using the OFV and
parameter precision to decide whether the covariate was of significance or
not. Covariates that were investigated included total body weight introduced
using allometric scaling (1), lean body weight (15) introduced using allomet-
ric scaling, creatinine clearance, HIV infection, and meal administration
(with a meal for patients in Cape Town, and without a meal for patients in
Durban). Creatinine clearance in ml/min was calculated using total body
weight in the Cockcroft-Gault equation using the formula below:
creatinine clearance 
140  age · total body weight · K
sCr
where K is a constant equal to 1.04 for women and 1.23 for men and sCr is
serum creatinine concentration in mol/liter.
Creatinine clearance was also calculated using lean body weight in a
modified Cockcroft-Gault equation as shown below:
creatinine clearance 
(140  age) · LBW
sCr
where LBW is the lean body weight. As the two different study sites had
different pharmacokinetic sampling schedules, this had the potential to
confound analyses when investigating the effect of food on drug admin-
istration. To evaluate the influence of pharmacokinetic sampling differ-
ences on the estimates of the model parameters of interest to be evaluated,
a stochastic simulation-estimation experiment of 200 samples was under-
taken using the Durban absorption model parameter estimates but with
the Cape Town pharmacokinetic sampling schedule. The bias and preci-
sion of the parameters from the simulation-estimation experiment were
obtained. However, it must be stated that another potential confounder is
the study site, since only Cape Town patients received food with their
tablets. This cannot be resolved by any means, and it is more likely that any
differences would be due to food effects.
Probability of target attainment. The probability, based on Monte
Carlo simulations, that a specific value of a pharmacodynamic index is
achieved or exceeded within a population of individuals is known as the
probability of target attainment (PTA) (23). The PTA is based upon inte-
gration of pharmacokinetic data in humans, using Monte Carlo simula-
tions, with antimicrobial pharmacodynamics as has been performed pre-
viously (5, 25). In our case, the pharmacodynamic index target was a
fAUC/MIC ratio of at least 100. Individual AUCs from the model were
obtained by integrating drug concentration predictions from 0 to 24 h
after drug administration. The AUC was then multiplied by 0.75, which is
the unbound fraction of ofloxacin in humans (19), to obtain the fAUC.
The final model was used to perform Monte Carlo simulations in 10,000
individuals to determine the PTA at various MICs (0.25, 0.5, 1.0, 2.0, 4.0,
and 8.0 mg/liter) and the PTA expectation based on the MIC distribution
in our study population. The PTA expectation was calculated using the
following equation:
i  1
n PTAi  Fi
where PTAi is the PTA for each MIC category and Fi is the fraction of the
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study population for the corresponding MIC category.
Dosing simulations. To optimize the dosing, further Monte Carlo sim-
ulations were performed using higher ofloxacin doses ranging from 800 mg to
1,600 mg daily in 200-mg increments toward dose optimization that would
lead to higher PTA expectation values. The final pharmacokinetic model im-
plemented in the software NONMEM was used for the simulations. The
simulations were carried out in 10,000 patients based on the covariate distri-
bution of our current data set. For each dose, the fAUC for each patient was
obtained. This was then used to calculate the PTA for each MIC in the ob-
served range (0.25 to 8 mg/liter), followed by the PTA expectation as de-
scribed above.
RESULTS
Thirty-eight patients were recruited from Cape Town and 27 pa-
tients from Durban, giving a total of 65 patients. Thirty-five (54%)
(18 from Cape Town and 17 from Durban) of the 65 patients were
HIV positive. There were 13 females (20%) in the study, all of
whom were from the Durban site. Table 1 further describes the
patient characteristics. Twenty-nine patients (16 from Cape Town
and 13 from Durban) received antiretroviral therapy comprising
efavirenz with 2 nucleoside reverse transcriptase inhibitors. Other
concomitant medicines included vitamin B complex, vitamin B6,
and cotrimozaxole in HIV-positive patients.
MIC distributions. MIC data were available from 22 of the
Durban patients and all 38 of the Cape Town patients. Five of
the Durban patients did not have MIC results due to lack of a
Mycobacterium tuberculosis isolate from these patients. Table 2
shows the percentages of MICs for each study site, together
with the overall MIC percentages of the pooled data. The Cape
Town MICs were significantly higher than the Durban MICs by
approximately one dilution. The geometric means (95% con-
fidence intervals) for the Cape Town and Durban MICs, re-
spectively, were 1.5 (1.2 to 2.0) and 0.8 (0.6 to 1.1) (Wilcoxon
rank-sum P  0.001).
Ofloxacin pharmacokinetics. A transit compartment (28)
model best described the absorption of ofloxacin, while a two-
compartment model with first-order elimination best described
the disposition of ofloxacin. Mixed-order elimination could not
be supported by the data. As can be seen from the derived param-
eters in Table 3 and Fig. 1b, there is a short early distribution
phase, followed by a longer terminal phase, similar to what has
been reported previously for ofloxacin (19). The final model had
two clearance pathways according to the equations below:
CLGFR  1  CrCl68 
CLnon-GFR  2  WT70 
3
4
(CL ⁄ F)i  [CLGFR  CLnon-GFR] · exp(CL)
where CLGFR is the glomerular filtration of ofloxacin, 1 is the
typical value that will be estimated by the model, CrCl is the cre-
atinine clearance of the individual subject i, which had a median
value of 68 ml/min, CLnon-GFR is the extraglomerular excretion
route of ofloxacin, 2 is the typical value that will be estimated, WT
is the weight of individual i, (CL/F)i is the total oral clearance of
ofloxacin for individual i, and CL is the population variability in
oral clearance for individual i.
The excretion of ofloxacin was best described using two
clearance pathways. One pathway represents glomerular filtra-
tion of ofloxacin. Creatinine clearance was a significant cova-
riate for this route of excretion. Substitution of lean body
TABLE 1 MDR-TB patient characteristics, ofloxacin pharmacokinetic
study, South Africa
Patient characteristic Median (2.5, 97.5 percentile)
Wt (kg) 55 (39, 80)
Lean body wt (kg) 46 (32, 54)
Ht (m) 1.67 (1.34, 1.84)
Age (yr) 34 (20, 63)
Body mass index (kg/m2) 19.3 (13.6, 36.4)
Creatinine clearance (ml/min)a 109 (69, 159)
a Calculated using Cockcroft-Gault equation using total body weight.
TABLE 2 Comparison of MICs for ofloxacin of multidrug-resistant M.
tuberculosis isolates from 2 sites in South Africa
Study site
% of isolates with ofloxacin MIC
(mg/liter) ofa:
0.5 1 2 4 8
Cape Town (n  38) 5 50 32 3 10
Durban (n  22) 41 50 5 0 5
Total (n  60) 18 50 22 2 8
a P value comparing proportion of isolates with specific MIC in Cape Town versus
Durban was 0.001.
TABLE 3 Parameter estimates from final model, ofloxacin







Glomerular filtration (liters/h/68 ml/min
CrCl)
3.7 (30) 26 (9)b
Extraglomerular excretion (liters/h/70 kg) 4.7 (28) 26 (9)b
Central vol (liters/46 kg LBW) 52 (20) 30 (32)
Peripheral vol (liters/70 kg) 40 (25)
Intercompartmental clearance (liters/h/70 kg) 59 (44)
Durban mean transit time (h) 0.74 (18) 54 (14)
Cape Town mean transit time (h) 1.76 (11) 54 (14)
Number of absorption transit compartments 6 (15)
Additive error (mg/liters) 0.6 (6)
Proportional error (%) 9.6 (9.4)
Covariance between random effects of
clearance and central vol of distribution
0.56 (25)
Derived parameters
Alpha half-life (h) 0.3





Peak concn in Durban patients (mg/liters) 10.4
Peak concn in Cape Town patients (mg/liters) 8.8
Time to peak concn in Durban patients (h) 1.2
Time to peak concn in Cape Town patients (h) 3
a RSE, relative standard error; PPV, population variability; CrCl, creatinine clearance
calculated using LBW in Cockcroft-Gault equation; LBW, lean body weight; kel,
elimination rate constant for the alpha phase; kel, elimination rate constant for the
beta phase.
b Variability was put on the overall clearance, which was the sum of the two different
pathways.
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weight (14) for total body weight in the Cockcroft-Gault equa-
tion further improved the model fit and resulted in a further
8-point decrease in the OFV (P  0.01) compared to a model
using total body weight. The second excretion route of ofloxa-
cin in our model represents extraglomerular routes, which
would be mainly active tubular secretion and a small amount of
biliary excretion (16). A significant covariate on this extraglo-
merular excretion of ofloxacin was total body weight, which
was introduced allometrically (1). We investigated lean body
weight as a covariate instead of total body weight on the extra-
glomerular route of excretion but found it to result in a higher
OFV than using total body weight. The central volume of dis-
tribution was allometrically scaled to lean body weight, while
the peripheral volume was scaled to total body weight, as was
the intercompartmental clearance. The central volume of dis-
tribution was initially scaled to the total body weight. This
resulted in a typical female having a volume 70% higher than
that for a male of the same weight and was accompanied by a
12-point drop in the OFV. However, when central volume was
scaled to lean body weight in the final model, which described
the data equally well, the gender effect on volume fell to 21%
and was no longer statistically significant. HIV infection was
not a significant covariate on ofloxacin pharmacokinetics. Ad-
ministration of ofloxacin after a meal (Cape Town patients)
resulted in a 2.4-fold increase in the mean transit time (MTT),
meaning food significantly delays the rate of absorption. Table
3 contains population parameter estimates, variability, and
precision from the final model. Figure 1 is a visual predictive
check of the final model, and it shows that the model describes
the data well.
As aforementioned, a stochastic simulation and estimation ex-
periment was carried out to determine whether this finding could
be an artifact of an altered sampling schedule. The bias and preci-
sion of the MTT from this finding were found to be 	0.9% and
13%, respectively, thus confirming that the finding was indepen-
dent of the sampling schedule.
Ofloxacin pharmacodynamics. The graphs of the PTA corre-
sponding to various ofloxacin doses from Monte Carlo simula-
FIG 1 (a) Visual predictive check of ofloxacin plasma concentrations in South African patients with MDR-TB in the final model stratified by the study site. Open
circles are the observations. Upper dotted line represents the 95th percentile of the observation. Continuous line represents the median of the observations. Lower
dotted line represents the 5th percentile of the observations. Shaded areas are the simulated confidence intervals for the corresponding percentiles. (b)
Log-normal plot showing ofloxacin concentration-time profile for the typical patient in Cape Town and in Durban.
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tions are shown in Fig. 2. Using the WHO recommended critical
concentration of 2.0 mg/liter, none of the doses examined (800 mg
to 1,600 mg) resulted in a PTA greater than 0.9. The 800-mg dose
provided a PTA greater than 0.9 only for patients with MICs less
than or equal to 0.5 mg/liter (Fig. 2), that is, 5.3% of Cape Town
patients and 40.9% of Durban patients. A dose of 1,400 mg was the
minimum dose achieving a PTA greater than 0.9 in patients with
an MIC equal to 1 mg/liter. The PTA expectation values for the
pooled study population and those for each study site are shown in
Table 4. Our simulations show that a 1,600-mg daily dose of
ofloxacin will achieve a PTA expectation value higher than 0.9 in
the Durban population, where the MICs were significantly lower
than for the Cape Town cohort.
DISCUSSION
This is the first report describing the pharmacokinetics and phar-
macodynamics of ofloxacin, taking into account Mycobacterium
tuberculosis susceptibility data from MICs in the study population.
We found that a high proportion of South African patients fail to
achieve the target fAUC/MIC of 100. We found significantly
higher MICs to ofloxacin for isolates in Cape Town (in the West-
ern Cape Province in South Africa) than in Durban (in KwaZulu-
Natal Province in South Africa). Due to the limited sample size,
these data may not represent the general epidemiological situa-
tion, so further study of ofloxacin MICs in South Africa is war-
ranted. However, resistance of the W-Beijing strain to fluoro-
quinolones has been documented (6), and the W-Beijing strain is
rapidly increasing in Cape Town (4). It is, however, difficult to
attribute the higher MICs found in Cape Town to the W-Beijing
strain, since Durban has a high prevalence of the F15/LAM4/KZN
strain (24), which is also resistant to fluoroquinolones. Further
studies to determine the prevalence of different types of strains
across South Africa and their susceptibilities to different drugs are
needed.
This is the first report to quantitatively describe ofloxacin ex-
cretion by glomerular and extraglomerular means, together with
the covariates influencing the different pathways. However, these
findings should be interpreted with caution since no direct in-
trarenal drug sampling was performed and the results are derived
solely from a mathematical perspective. Our finding that calcula-
tion of glomerular filtration using lean body weight rather than
total body weight described the glomerular clearance better is in
agreement with the fact that renal function is more closely related
to lean body weight (15). This finding is especially important in
our setting where some of the patients are obese according to their
high body mass indices. Although some papers indicate that hy-
perfiltration may occur in obesity (3), more recent papers show
that using the Cockcroft and Gault formula with an adjustment
for lean body weight is the best measure for renal function in
obesity (17). From our model, it can be seen that patients with
renal insufficiency or patients with lower body weight would have
lower clearance of the drug and hence higher plasma concentra-
tions. When considering administration of higher doses of ofloxa-
cin, it may be important to consider individual variation in body
weight and renal function. HIV infection did not significantly al-
ter ofloxacin pharmacokinetics, in accord with previous reports
(33).
Our simulations of higher doses are based on first-order elim-
ination of ofloxacin. We investigated mixed-order elimination of
the drug in our study population, but this was not found to be
statistically significant at daily doses of 800 mg. Hence, our model
would underpredict exposure at higher doses, if saturable kinetics
occurs.
With a MIC of 2.0 mg/liter (the WHO critical concentration),
none of the doses simulated would result in an acceptable PTA,
TABLE 4 PTA expectation values, ofloxacin pharmacokinetic study in










800 0.45 0.33 0.65
1,000 0.57 0.46 0.76
1,200 0.66 0.57 0.83
1,400 0.73 0.64 0.89
1,600 0.77 0.70 0.91
fAUC/MIC  40
800 0.83 0.77 0.94
1,000 0.87 0.83 0.95
1,200 0.90 0.87 0.96
1,400 0.92 0.89 0.97
1,600 0.93 0.91 0.97
FIG 2 (a) Probability of target attainment (fAUC/MIC  100) by Mycobac-
terium tuberculosis isolate MIC for ofloxacin for various daily doses of ofloxa-
cin. The fraction of the population with each MIC is also shown on the same
graph for both Durban and Cape Town patients. (b) Probability of target
attainment (fAUC/MIC  40) by Mycobacterium tuberculosis isolate MIC of
ofloxacin for various daily doses of ofloxacin. The fraction of the population
with each MIC is also shown on the same graph for both Durban and Cape
Town patients.
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suggesting that the critical concentration should be revised down-
ward. Indeed, other authors have proposed a cutoff of 	1.0 mg/
liter based upon the MIC distribution from clinical strains in Swe-
den (2). Our PTA expectation results support this argument. This
is apparent even though the MIC determination method in our
study differs slightly from the Swedish study, which defined the
MIC as the lowest concentration of drug that inhibited 
99% of
the bacterial population. This would result in a PTA greater than
0.9 but only when using a daily dose of at least 1,400 mg (Fig. 2a).
The safety of these higher ofloxacin doses needs evaluation, as
fluoroquinolones have side effects such as dysglycemia, tendon-
itis, anemia (16), and QT interval prolongation (8), whose inci-
dence and severity may increase with higher doses. This is espe-
cially of concern when one considers the long duration of
MDR-TB treatment. For the current 800-mg daily dose, we pro-
pose a cutoff of 0.5 mg/liter, as can be seen in Fig. 2a. However, if
a target fAUC/MIC ratio of 40 is used, a breakpoint of 1 mg/liter is
recommended, as can be seen in Fig. 2b. In either case, ofloxacin
should not be used in patients with a MIC of 
1 mg/liter. There-
fore, one can speculate that the way ofloxacin is currently being
used might even be promoting resistance among fluoroquinolo-
nes since it is known that there is cross-resistance among the fluo-
roquinolones (9, 32).
Perhaps ofloxacin continues to be used because it is relatively
inexpensive. However, it is unclear whether this is rational drug
use since our data suggest otherwise. As mentioned above, levo-
floxacin has about half the MIC of ofloxacin; hence, one can ex-
pect a similar dose of levofloxacin to do much better than ofloxa-
cin. The same goes for moxifloxacin. Use of these alternative drugs
would significantly increase the PTA expectation in patients with
tuberculosis and decrease the likelihood of development of resis-
tance.
Limitations. We have used a fAUC/MIC ratio of 100 as the
ideal minimum value based upon studies using animals infected
with Mycobacterium tuberculosis (31) and data from human stud-
ies (30) and in vitro studies (12). There is some disagreement over
what the ideal AUC/MIC ratio should be for fluoroquinolones
(29), which may vary for different types of bacteria (36) and dur-
ing different phases of TB treatment. We have assumed concen-
tration-independent protein binding of ofloxacin in accordance
with findings in healthy volunteers (19). However, it is possible
that at higher concentrations, ofloxacin protein binding may be
concentration dependent as reported in a murine study (31).
Conclusion. Our data suggest that the currently recom-
mended ofloxacin dose of 800 mg per day is too low for the treat-
ment of MDR-TB in South Africa. If higher doses of ofloxacin
cannot be used due to safety reasons, a more potent fluoroquin-
olone such as levofloxacin or moxifloxacin should be used.
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